日韩精品-污污网站在线观看-夜夜操夜夜爽-天天躁日日躁aaaa视频-99热视-在线免费观看av片-国产美女主播-播金莲一级淫片aaaaaaa-国产大奶-激情久久婷婷-色欧美在线-亚洲精品婷婷-荡女精品导航-av片亚洲-91.色-国产高清第一页-欧美一区二区免费在线观看-91av国产视频-日韩一级视频在线观看-免费黄色在线网址-欧美交换配乱吟粗大25p-筱崎爱裸乳照无奶罩-9191国产精品-久久av中文-久久一区欧美-自拍偷拍21p-国产成人亚洲综合无码-人妻被按摩师玩弄到潮喷-成人狠狠干-肉嫁高柳在线

Welcome to Linuo Group!HomeBusiness License
  • CN

  • WeChat

  • Mobile Site

  • Search

力諾資訊

Keyuan Pharma Wins 2025 Forbes China Industry Development Innovative Brand Award

2025.04.02

Shandong Keyuan Pharmaceutical Co., Ltd. has been awarded the 2025 Forbes China Industry Development Innovative Brand Award at the 2025 Forbes China Industry Development Pioneers Selection held in Shanghai on March 22nd, in recognition of its exceptional innovation capabilities and significant industry influence.

The accolade not only represents high recognition of Keyuan Pharma's years of dedicated efforts in the field of chemical APIs and preparations but also stands as a powerful testament to its leapfrog development driven by innovation amid the adjustments in the global industrial landscape.

Jointly initiated by Frost & Sullivan, a world-renowned growth consulting firm, and Forbes China Group, the 2025 Forbes China Industry Development Pioneers Selection aims to identify outstanding enterprises and individuals in key sectors such as new energy, AI technology, mass consumption, and biomedicine that are driving industry transformation with an innovative spirit. Keyuan Pharma's success in standing out this time underscores its prominent position in the chemical drug sector.

Founded in 2004, Keyuan Pharmaceutical has focused on the R&D, production, and sales of chemical APIs and preparations. It has established three core product lines: anti-diabetic, cardiovascular, and anesthetic drugs, and ranks as a backbone enterprise in the field of chemical synthetic drugs in Shandong Province.

Innovation is the core driving force behind Keyuan Pharma's development. The company has continuously increased its R&D investment, actively explored cutting-edge technologies, and improved its innovation system. Recently, Keyuan Pharma obtained the utility model patent authorization for "a raw material preliminary processing and drying device for metformin hydrochloride processing," marking the fourth patent authorization it has received this year. A series of patent achievements have provided solid support for improving product quality, enhancing production efficiency, and controlling costs, helping the company gain an edge in the fierce market competition.